EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Total metabolic tumor volume on 18 F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy

Pierre Tricarico iD, David Chardin, Nicolas Martin iD, Sara Contu iD, Florent Hugonnet, Josiane Otto, Olivier Humbert

Journal for ImmunoTherapy of Cancer · 2024-04 · 12 (4) · e007628

DOI: 10.1136/jitc-2023-007628 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 22.04.2024. Verfasst von Pierre Tricarico und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Centre Antoine-Lacassagne, Nice, France pierretricarico@gmail.com. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Lung Neoplasms, Positron Emission Tomography Computed Tomography, Tumor Burden. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: 3IA cote d'azur.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Because of atypical response imaging patterns in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs), new biomarkers are needed for a better monitoring of treatment efficacy. The aim of this prospective study was to evaluate the prognostic value of volume-derived positron-emission tomography (PET) parameters on baseline and follow-up 18 F-fluoro-deoxy-glucose PET ( 18 F-FDG-PET) scans and compare it with the conventional PET Response Criteria in Solid Tumors (PERCIST).

Methods

Patients with metastatic NSCLC were included in two different single-center prospective trials. 18 F-FDG-PET studies were performed before the start of immunotherapy (PET baseline ), after 6–8 weeks (PET interim 1) and after 12–16 weeks (PET interim 2) of treatment, using PERCIST criteria for tumor response assessment. Different metabolic parameters were evaluated: absolute values of maximum standardized uptake value (SUVmax) of the most intense lesion, total metabolic tumor volume (TMTV), total lesion glycolysis (TLG), but also their percentage changes between PET studies (ΔSUVmax, ΔTMTV and ΔTLG). The median follow-up of patients was 31 (7.3–31.8) months. Prognostic values and optimal thresholds of PET parameters were estimated by ROC (Receiver Operating Characteristic) curve analysis of 12-month overall survival (12M-OS) and 6-month progression-free survival (6M-PFS). Tumor progression needed to be confirmed by a multidisciplinary tumor board, considering atypical response patterns on imaging.

Results

110 patients were prospectively included. On PET baseline , TMTV was predictive of 12M-OS [AUC (Area Under Curve) =0.64; 95% CI: 0.61 to 0.66] whereas SUVmax and TLG were not. On PET interim 1 and PET interim 2, all metabolic parameters were predictive for 12M-OS and 6M-PFS, the residual TMTV on PET interim 1 (TMTV 1 ) being the strongest prognostic biomarker (AUC=0.83 and 0.82; 95% CI: 0.74 to 0.91, for 12M-OS and 6M-PFS, respectively). Using the optimal threshold by ROC curve to classify patients into three TMTV 1 subgroups (0 cm 3 ; 0–57 cm 3 ; >57 cm 3 ), TMTV 1 prognostic stratification was independent of PERCIST criteria on both PFS and OS, and significantly outperformed them. Subgroup analysis demonstrated that TMTV 1 remained a strong prognostic biomarker of 12M-OS for non-responding patients (p=0.0003) according to PERCIST criteria. In the specific group of patients with PERCIST progression on PET interim 1, low residual tumor volume (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Lung NeoplasmsPositron Emission Tomography Computed TomographyTumor BurdenImmunotherapyHumansMaleFemaleMiddle AgedAgedProspective StudiesCarcinoma, Non-Small-Cell LungAdultNeoplasm MetastasisImmune Checkpoint InhibitorsAged, 80 and over

Stichwörter der Autor:innen

Biomarkers, TumorImmune Checkpoint InhibitorsImmunotherapyNon-Small Cell Lung CancerTumor Biomarkers

Substanzen

Fluorodeoxyglucose F18Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Centre Antoine-Lacassagne, Nice, France pierretricarico@gmail.com.
  • Department of Nuclear Medicine, Centre Antoine-Lacassagne, Nice, France.
  • IBV, Université Côte d'Azur, CNRS, Inserm, Nice, France.
  • Department of Medical Oncology, Centre Antoine-Lacassagne, Nice, France.
  • Department of Biostatistics, Centre Antoine-Lacassagne, Nice, France.
  • Department of Nuclear Medicine, Centre Hospitalier Princesse Grâce, Monaco.

ORCID-Profile: Pierre Tricarico, Nicolas Martin, Sara Contu

Förderung

  • 3IA cote d'azur

Zitieren

APA

Tricarico, P., Chardin, D., Martin, N., Contu, S., Hugonnet, F., Otto, J., & Humbert, O. (2024). Total metabolic tumor volume on 18 F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy. Journal for ImmunoTherapy of Cancer, 12(4), e007628. https://doi.org/10.1136/jitc-2023-007628

Vancouver

Tricarico P, Chardin D, Martin N, Contu S, Hugonnet F, Otto J, et al. Total metabolic tumor volume on 18 F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy. Journal for ImmunoTherapy of Cancer. 2024;12(4):e007628. doi:10.1136/jitc-2023-007628

BibTeX
@article{Tricarico2024,
  author = {Tricarico, Pierre and Chardin, David and Martin, Nicolas and Contu, Sara and Hugonnet, Florent and Otto, Josiane and Humbert, Olivier},
  title = {Total metabolic tumor volume on 18 F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {4},
  pages = {e007628},
  doi = {10.1136/jitc-2023-007628}
}
Kostenlos starten →